Alessandra Ferrajoli, MD
M.D. Anderson Cancer Center · UT M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alessandra Ferrajoli, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06967610 · Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).M.D. Anderson Cancer Center · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL) · principal investigator
- N/ANCT05879133 · HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT05317936 · Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxM.D. Anderson Cancer Center · terminated · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT03128879 · Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT01924169 · Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · terminated · Hematologic Disorder · principal investigator
- Ph2NCT01446133 · Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)M.D. Anderson Cancer Center · active not recruiting · Leukemia, Lymphoma · principal investigator
- Ph2NCT00940342 · Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- N/ANCT00503256 · Genetic Study of Chronic Lymphocytic Leukemia FamiliesM.D. Anderson Cancer Center · unknown · Leukemia · principal investigator
- Ph2NCT00381004 · FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00267059 · Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia, Leukemia · principal investigator
- Ph2NCT00071396 · Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid DisordersM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.